10x Genomics, Inc. (TXG)
TXG moved a median of +0.14% 30 minutes after news, and +0.71% by the close. How TXG actually reacts to news — the realized, point-in-time move the market made, measured across 334 labeled events over the last three years with zero look-ahead.
TXG’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.02% | 49% | 334 |
| 30-min | +0.14% | 52% | 334 |
| 60-min | +0.54% | 61% | 334 |
| to close | +0.71% | 64% | 332 |
| Middle 50% of TXG reactions | -0.87% to +1.55% |
|---|---|
| Median reaction (30-min) | +0.14% |
| Measured reactions | 334 |
Half of all 10x Genomics, Inc. news events land between -0.87% and +1.55% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How TXG reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 14 | +0.94% | 64% | +0.91% |
| Analyst downgrades | 27 | -0.17% | 44% | +0.62% |
| Coverage initiations | 19 | +3.39% | 63% | +2.99% |
| Rating reiterations | 116 | -0.00% | 50% | +0.61% |
| Price-target raises | 18 | -0.36% | 39% | +2.30% |
| Price-target cuts | 40 | +0.04% | 50% | +0.37% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how TXG ranks against every other measured name →
That’s how TXG usually reacts — get an email when it moves on news →Email me when TXG moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TXG's baseline. Nothing else.
Recent TXG events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| 10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026 | Press release | PR Newswire | +2.01% | +5.03% | |
| 10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers | Press release | PR Newswire | -3.84% | -0.69% | |
| 10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions | Press release | PR Newswire | +2.35% | +1.36% | |
| 10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands | Press release | PR Newswire | +2.35% | +1.36% | |
| Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research | Press release | PR Newswire | -0.57% | +1.86% | |
| 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences | Press release | PR Newswire | +0.37% | +0.20% | |
| Form 10-Q 10x Genomics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.52% | +16.22% | |
| 10x Genomics Reports Second Quarter 2026 Financial Results | Press release | PR Newswire | +2.52% | +16.22% | |
| Form 8-K 10x Genomics, Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +2.52% | +16.22% | |
| 10x Genomics and Lausanne University Hospital Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies for Cancer Care | Press release | PR Newswire | +1.27% | -2.07% | |
| 10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026 | Press release | PR Newswire | -0.19% | -1.00% | |
| 10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer | Press release | PR Newswire | +0.19% | +2.10% | |
| 10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group | Press release | PR Newswire | +3.57% | +3.98% | |
| Form 8-K 10x Genomics, Inc. For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | +3.57% | +3.98% | |
| Form 10-Q 10x Genomics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.33% | +2.52% | |
| 10x Genomics Reports First Quarter 2026 Financial Results | Press release | PR Newswire | -1.33% | +2.52% | |
| Form 8-K 10x Genomics, Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -1.33% | +2.52% | |
| 10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference | Press release | PR Newswire | +0.58% | +5.81% | |
| Form DEF 14A 10x Genomics, Inc. For: Jun 04 | SEC filing · Form DEF | SEC EDGAR | +0.77% | +1.14% | |
| Form DEFA14A 10x Genomics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.77% | +1.14% | |
| 10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and Understood | Press release | PR Newswire | +0.70% | -4.43% | |
| 10x Genomics to Report First Quarter 2026 Financial Results on May 7, 2026 | Press release | PR Newswire | -0.57% | -0.47% | |
| Bioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical Labs | Press release | PR Newswire | +3.61% | +3.52% | |
| PerturbAI Launches from Stealth, Unveils the World's Largest In Vivo CRISPR Atlas | Press release | PR Newswire | +2.49% | +7.23% | |
| 10x Genomics to Participate in the 46th Annual TD Cowen Health Care Conference | Press release | PR Newswire | +0.05% | -1.41% | |
| Form 10-K 10x Genomics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.82% | -5.82% | |
| Form S-8 10x Genomics, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.84% | +3.73% | |
| 10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026 | Press release | PR Newswire | +2.82% | -5.82% | |
| Form 8-K 10x Genomics, Inc. For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | +2.82% | -5.82% | |
| PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology | Press release | PR Newswire | -1.24% | -1.70% | |
| 10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 | Press release | PR Newswire | +1.47% | -3.12% | |
| 10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease | Press release | PR Newswire | -2.10% | -5.44% | |
| 10x Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling | Press release | PR Newswire | -2.10% | -5.44% | |
| Cancer Research Institute Launches Transformative AI-Driven Immuno-Oncology Initiative Powered by 10x Genomics Technology | Press release | PR Newswire | -2.10% | -5.44% | |
| Form 8-K 10x Genomics, Inc. For: Jan 11 | SEC filing · Form 8-K | SEC EDGAR | +0.48% | +0.53% | |
| 10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results | Press release | PR Newswire | -2.10% | -5.44% | |
| 10x Genomics to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | PR Newswire | -0.81% | +1.05% | |
| New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium | Press release | PR Newswire | -1.92% | -0.45% | |
| Form 8-K 10x Genomics, Inc. For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +2.41% | +3.65% | |
| 10x Genomics to Participate in the Wolfe Research Healthcare Conference 2025 | Press release | PR Newswire | +2.05% | +0.54% | |
| Form 10-Q 10x Genomics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.66% | +5.39% | |
| 10x Genomics Reports Third Quarter 2025 Financial Results | Press release | PR Newswire | -1.66% | +5.39% | |
| Form 8-K 10x Genomics, Inc. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -1.66% | +5.39% | |
| 10x Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research | Press release | PR Newswire | +2.14% | -1.60% | |
| 10x Genomics and Anthropic Partner to Make Single Cell and Spatial Analysis More Accessible Through Claude for Life Sciences | Press release | PR Newswire | +0.28% | +4.20% | |
| 10x Genomics to Report Third Quarter 2025 Financial Results on November 6, 2025 | Press release | PR Newswire | -0.42% | -2.96% | |
| CLISEQ, 10X Genomics and Weizmann Institute to Investigate Single Cell Applications in Hematology Clinical Diagnostics | Press release | PR Newswire | -0.25% | -2.53% | |
| 10x Genomics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference | Press release | PR Newswire | -0.07% | +0.00% | |
| 10x Genomics Launches Xenium Protein, Advancing Spatial Biology by Enabling Same-Cell RNA and Protein Analysis | Press release | PR Newswire | -0.33% | — | |
| Form 10-Q 10x Genomics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -12.90% | -15.18% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TXG section they belong to.
Where else TXG is measured.
TXG earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is 10x Genomics, Inc.'s median reaction calculated?
Every labeled TXG news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 334 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of TXG's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TXG's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.